News

Pilot Study Shows Spinal Realignment Improves Systolic Hypertension


 

NEW YORK — Spinal manipulation reduced the systolic pressure in selected patients with hypertension in a controlled pilot study with 50 patients.

Realignment of the atlas vertebra seemed to lower the systolic blood pressure of 25 patients during 8 weeks of follow-up without drug therapy. A control group of 25 patients who underwent a mock realignment had no reduction in their systolic pressure, Dr. George L. Bakris and his associates reported in a poster at the annual meeting of the American Society of Hypertension.

Anatomical abnormalities of the cervical spine at the level of the atlas vertebra are associated with relative ischemia of the brainstem circulation and increased blood pressure. Impaired blood supply to the brain may affect the sympathetic nervous system and sympathetic tone, said Dr. Bakris, professor of preventive medicine and director of the Hypertension/Clinical Research Center at Rush University in Chicago.

The pilot study enrolled patients with stage 1 hypertension who had no neck pain and evidence of atlas misalignment on preliminary screening. The patients were either withdrawn from their antihypertensive medications or had been treatment naive at entry to the study.

The atlas realignment procedure used was the standard treatment of the National Upper Cervical Chiropractic Association. Briefly, the patient's head is placed on a curved, mastoid support, which acts as a fulcrum. The patient's nondominant hand is positioned around the dominant wrist, and then the dominant hand is placed on a “corner” of the atlas's transverse process. External nudges are used to cause the atlas vertebra to recoil into a normal alignment.

The control patients underwent a sham procedure designed so that correct alignment wasn't achieved.

At baseline, average systolic blood pressure was 150 mm Hg in the control patients and 147 mm Hg in the patients who then underwent a real realignment procedure.

The average systolic pressure of the actively treated patients began to show a statistically significant drop relative to the control patients at 3 weeks after treatment, and their systolic pressure steadily declined during the following 5 weeks. By 8 weeks after treatment, the average systolic pressure in the treated group was less than 130 mm Hg. By contrast, the control group had no drop in average systolic pressure throughout follow-up. At 8 weeks after their sham procedure, the average systolic pressure was unchanged, at about 148 mm Hg.

Recommended Reading

Valsartan Cuts CRP Levels, Lowers Blood Pressure
MDedge Family Medicine
Heart Symptoms Prior to MI Missed in Primary Care Settings
MDedge Family Medicine
Urban Youth Rarely Screened For CVD, Even When Overweight : More than a quarter of the children turned out to be positive for hypertension, diabetes, or dyslipidemia.
MDedge Family Medicine
Fiber Intake Predicts CV Disease Risk in Teens
MDedge Family Medicine
Subclinical Atherosclerosis Seen in Inflammatory Arthritis
MDedge Family Medicine
Low Vitamin D May Elevate Hypertension Risk
MDedge Family Medicine
Combo Antihypertensives Should Be First Line : Nearly half of patients on two agents met diastolic goals compared with a third of those on monotherapy.
MDedge Family Medicine
Aliskiren Plus a Diuretic Controls 24-Hour Blood Pressure
MDedge Family Medicine
Watch for Statin-Rx Interactions, Side Effects
MDedge Family Medicine
What is the best management for patients who have a TIA while on aspirin therapy?
MDedge Family Medicine